Fig. 2 Risk of bias summary for included studies.
Note: A ”+” stands for low risk, ”−” for high risk, and ”?” for unclear
risk.
Figure 3, including four articles,
shows a forest plot of the risk
ratio of patients whose MRS score was 0-1 at day 90 between fingolimod
plus standardized treatment and standardized treatment alone. This
finding suggested that the risk ratio of the proportion of patients
whose MRS score was 0-1 at day 90 between fingolimod plus standardized
treatment and standardized treatment alone was 2.59 (95%CI, 1.48 to
4.56). A random-effect model was used. Sensitivity analyses were
performed by removing each study in turn and re-analyzed it. No studies
were found to significantly affect heterogeneity.